BioSpace News Archive

Investment is in Ideal Option, a leading provider of Medication-Assisted Treatment and behavioral counseling services for individuals suffering from Opioid Use Disorder

Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 2:45 pm – 3:10 pm ET in New York.

Up-Listing to NASDAQ to Provide Greater Exposure to U.S. Investors

Agreement to develop technology supporting the discovery of neoantigen-reactive T cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors.

Mesoblast Limited today announced that the 159-patient randomized placebo-controlled Phase 2b trial evaluating its allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in the treatment of end-stage heart failure patients implanted with a left ventricular assist device (LVAD) has been selected as a late-breaking presentation at the 2018 Scientific Sessions of the American Heart Association being held in Chicago from November 11-13.

CathVision ApS announced today that the company received ISO 13485:2016 certification for Medical Device and Quality Management Systems from Lloyd’s Register.

Based on its interview with Dr. Leslie Norins, CEO of Alzheimer’s Germ Quest, Inc., Contagion, a newsmagazine for infectious disease specialists indicated the “germ theory” of Alzheimer’s disease causation was gaining traction.

Kurin Inc. announced today that it has been awarded a Med/Surg Group agreement in the Safety Phlebotomy Category with Premier.

Amedisys, Inc. announced today that its subsidiary, Associated Home Care, closed on its acquisition of Bring Care Home, a personal care provider in northeastern Massachusetts.

Amicus Therapeutics today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe disease will be included at the 23rd International Congress of the World Muscle Society, to be held October 2-6, 2018 in Mendoza, Argentina.